

likely to be hospitalized than non-pregnant women. Infants too young to be vaccinated are also vulnerable to severe outcomes and death due to influenza and pertussis disease. Maternal immunization is an important strategy to protect both pregnant women and their young infants from vaccine-preventable disease, and both the Advisory Committee for Immunization Practices and the American College of Obstetricians and Gynecologists recommend that all pregnant women receive immunizations against influenza and pertussis disease during every pregnancy. However, despite evidence to support clear health benefits of maternal immunization for pregnant women and infant, immunization coverage in pregnant women remains low. In addition, many pregnant women reported that their provider did not recommend that they receive vaccines, indicating ongoing missed opportunities during healthcare interactions. Therefore, it is critical to understand the barriers that both prevent pregnant women from receiving recommended vaccinations and those that prevent obstetrical care providers from recommending and administering vaccines within their practices. Doing so will help to advance maternal immunization efforts and increase coverage to maximize the number of pregnant women and young infants that can benefit from these strategies.

Through their analysis and discussion, the NVAC identified five major areas of opportunity:

1. Enhancing communication to address the safety and effectiveness of all currently recommended immunizations during pregnancy;
2. Maximizing obstetric provider recommendation and administration of recommended maternal immunizations;
3. Focusing efforts to improve financing for immunization services during pregnancy and postpartum;
4. Supporting efforts to increase the use of electronic health records (EHRs) and Immunization Information Systems (IISs) among obstetrical care providers; and
5. Recognizing and addressing current vaccine liability law barriers to optimize investigations and uptake of recommended and future vaccines during pregnancy.

Within each area the NVAC report details key recommendations to overcoming challenges in these areas.

## II. Request for Comment

NVPO, on behalf of the NVAC Maternal Immunizations Working Group, requests input on the draft report and draft recommendations. In addition

to general comments on the draft report and draft recommendations, NVPO is seeking input on efforts or barriers to maternal immunizations not represented in the report where HHS efforts could advance maternal immunization efforts. Please limit your comments to six (6) pages.

## III. Potential Responders

HHS invites input from a broad range of stakeholders including individuals and organizations that have interests in maternal immunization efforts and the role of HHS in advancing those efforts.

Examples of potential responders include, but are not limited to, the following:

- general public;
- advocacy groups, non-profit organizations, and public interest organizations;
- academics, professional societies, and healthcare organizations;
- public health officials and immunization program managers;
- obstetrical care provider groups including all physician and non-physician providers that administer healthcare services to pregnant women, including pharmacists; and
- representatives from the private sector.

When responding, please self-identify with any of the above or other categories (include all that apply) and your name. Anonymous submissions will not be considered. Written submissions should not exceed six (6) pages. Please do not send proprietary, commercial, financial, business, confidential, trade secret, or personal information.

Dated: March 13, 2014.

**Bruce Gellin,**

*Deputy Assistant Secretary for Health, Director, National Vaccine Program Office, Executive Secretary, National Vaccine Advisory Committee.*

[FR Doc. 2014-06594 Filed 3-25-14; 8:45 am]

**BILLING CODE 4150-44-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Partnerships To Advance the National Occupational Research Agenda (NORA)

**AGENCY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of public meeting.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following public meeting, which will be held as a webinar: “Partnerships to Advance the National Occupational Research Agenda (NORA)”.

*Public Meeting Time and Date:* 1 p.m.–2:30 p.m. EDT, April 22, 2014.

*Place:* Online and teleconference only, see details below.

*Purpose of the Meeting:* The National Occupational Research Agenda (NORA) has been structured to engage partners with each other and/or with NIOSH to advance NORA priorities. The NORA Liaison Committee continues to be an opportunity for representatives from organizations with national scope to learn about NORA progress and to suggest possible partnerships based on their organization’s mission and contacts. This opportunity is now structured as a public meeting via the Internet to attract participation by a larger number of organizations and to further enhance the success of NORA. Some of the types of organizations of national scope that are especially encouraged to participate are employers, unions, trade associations, labor associations, professional associations, and foundations. Others are welcome.

This meeting will include:

- Updates from NIOSH leadership on NORA and on plans for evaluating the second decade of NORA;
- A discussion of a variety of metrics NIOSH is considering for measuring its performance as a research agency;
- Brief written updates from most of the NORA Sector Councils on their progress, priorities, and implementation plans to date, likely including the NORA Agriculture, Forestry and Fishing; Construction; Healthcare and Social Assistance; Manufacturing; Mining; Oil and Gas Extraction; Public Safety; Services; Transportation, Warehousing and Utilities; and Wholesale and Retail Trade Sector Councils; and

• Time to ask questions and discuss partnership opportunities.

*Status:* The meeting is open to the public, limited only by the capacities of the conference call and online system for sharing slides. Everyone can participate through the Internet (to see the slides) and a teleconference call (capacity 50). Each participant is requested to register for the free meeting by sending an email to [noracoordinator@cdc.gov](mailto:noracoordinator@cdc.gov) containing the participant’s name, organization name, and contact telephone number on the day of the meeting. Requirements

include: computer, Internet connection, and telephone, preferably with 'mute' capability. An email confirming registration will include the details needed to participate in the Web meeting.

**Background:** NORA is a partnership program to stimulate innovative research in occupational safety and health leading to improved workplace practices. Unveiled in 1996, NORA has become a research framework for the nation. Diverse parties collaborate to identify the most critical issues in workplace safety and health. Partners then work together to develop goals and objectives for addressing those needs and to move the research results into practice. The NIOSH role is facilitator of the process. For more information about NORA, see <http://www.cdc.gov/niosh/nora/about.html>.

Since 2006, NORA has been structured according to industrial sectors. Ten major sector groups have been defined using the North American Industrial Classification System (NAICS). After receiving public input through the Web and town hall meetings, ten NORA Sector Councils defined sector-specific strategic plans for conducting research and moving the results into widespread practice. To view the National Sector Agendas, see <http://www.cdc.gov/niosh/nora/>.

**FOR FURTHER INFORMATION CONTACT:** Sidney C. Soderholm, Ph.D., NORA Coordinator, Email [noracoordinator@cdc.gov](mailto:noracoordinator@cdc.gov), telephone (202) 245-0665.

Dated: March 20, 2014.

**John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2014-06629 Filed 3-25-14; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention—Health Disparities Subcommittee (HDS)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned subcommittee:

**Time and Date:** 9:00 a.m.–3:30 p.m., EST, April 16, 2014.

**Place:** CDC, Building 21, Room 1204A, 1600 Clifton Road NE., Atlanta, Georgia 30333.

**Status:** Open to the public, limited only by the space available. The meeting room accommodates approximately 20 people. The public is welcome to participate during the public comment period, tentatively scheduled from 3:15 p.m. to 3:30 p.m. This meeting is also available by teleconference. Please dial (877) 496-4855 and enter code 4363556.

**Purpose:** The Subcommittee will provide advice to the CDC Director through the ACD on strategic and other health disparities and health equity issues and provide guidance on opportunities for CDC.

**Matters for Discussion:** The Health Disparities Subcommittee members will discuss some of the current health equity activities at CDC, including those related to chronic diseases, as well as discuss health equity recommendations to the CDC ACD.

The agenda is subject to change as priorities dictate.

#### Web Links

##### Connection-1

<http://wm.onlinevideoservice.com/CDC1>

##### Flash Connection-3 (For Safari and Google Chrome Users)

<http://www.onlinevideoservice.com/clients/CDC/?mount=CDC3>

If you are unable to connect using the link, copy and paste the link into your web browser.

Captions are only available on the Windows Media links Connections-1.

Viewer's report is given the next day.

**Number for Technical Support:** 404-639-3737.

##### Contact Person for More Information:

Leandris Liburd, Ph.D., M.P.H., M.A., Designated Federal Officer, Health Disparities Subcommittee, ACD, CDC, 1600 Clifton Road NE., Mailstop K-77, Atlanta, Georgia 30333, Telephone (770) 488-8343, Email: [LEL1@cdc.gov](mailto:LEL1@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Gary J. Johnson,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 2014-06624 Filed 3-25-14; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2013-N-1089]

#### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Recommended Glossary and Educational Outreach To Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, [PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** On January 28, 2014, the Agency submitted a proposed collection of information entitled "Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use" to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0553. The approval expires on March 31, 2017. A copy of the supporting statement for this information collection is available on the Internet at <http://www.reginfo.gov/public/do/PRAMain>.

Dated: March 20, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014-06617 Filed 3-25-14; 8:45 am]

**BILLING CODE 4160-01-P**